MDR-话题@MedSci

#MDR#

15篇内容 | 655人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1991686, encodeId=6ca319916868c, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=Neurology：24例LGMDR12成人患者两年随访的前瞻性自然史研究：定量MRI和临床结果评估, objectType=article, longId=730597, objectId=60fbe30597e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60fbe30597e1, replyNumber=0, likeNumber=49, createdTime=2022-10-12, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60fbe30597e1, moduleTitle=Neurology：24例LGMDR12成人患者两年随访的前瞻性自然史研究：定量MRI和临床结果评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60fbe30597e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991685, encodeId=0e3a1991685f5, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=沙巍解读：在MDR-TB高负担国家推广贝达喹啉对患者治疗结局的影响, objectType=article, longId=220569, objectId=2313220569b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2313220569b8, replyNumber=0, likeNumber=38, createdTime=2022-08-10, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2313220569b8, moduleTitle=沙巍解读：在MDR-TB高负担国家推广贝达喹啉对患者治疗结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2313220569b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991684, encodeId=058e1991684c3, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=数坤冠脉AI、肺炎AI获欧盟MDR CE证书智能医疗健康服务普惠全球医患, objectType=article, longId=212348, objectId=d93c21234896, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d93c21234896, replyNumber=0, likeNumber=39, createdTime=2021-07-17, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d93c21234896, moduleTitle=数坤冠脉AI、肺炎AI获欧盟MDR CE证书智能医疗健康服务普惠全球医患, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d93c21234896)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991683, encodeId=f3aa1991683d4, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=Brit J Cancer：D133可通过AKT/NF-κB/MDR1通路逆转结直肠癌的耐药性, objectType=article, longId=190698, objectId=0e2a19069834, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e2a19069834, replyNumber=0, likeNumber=52, createdTime=2020-06-29, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e2a19069834, moduleTitle=Brit J Cancer：D133可通过AKT/NF-κB/MDR1通路逆转结直肠癌的耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e2a19069834)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991682, encodeId=5a251991682c3, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=CIMDR苏州举办，TUV南德专业解读医疗器械领域新近法规, objectType=article, longId=180182, objectId=23e01801827d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23e01801827d, replyNumber=0, likeNumber=40, createdTime=2019-11-12, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23e01801827d, moduleTitle=CIMDR苏州举办，TUV南德专业解读医疗器械领域新近法规, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23e01801827d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991681, encodeId=5fb919916819d, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=TUV南德正式获得欧盟医疗器械新法规 (MDR) 发证资质授权, objectType=article, longId=166722, objectId=6cb3166e22e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cb3166e22e5, replyNumber=0, likeNumber=43, createdTime=2020-04-07, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cb3166e22e5, moduleTitle=TUV南德正式获得欧盟医疗器械新法规 (MDR) 发证资质授权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cb3166e22e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991680, encodeId=f2351991680b3, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=MDR、XDR、PDR多重耐药菌暂行标准定义——国际专家建议, objectType=article, longId=154196, objectId=a4fb154196dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4fb154196dc, replyNumber=0, likeNumber=48, createdTime=2019-05-05, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4fb154196dc, moduleTitle=MDR、XDR、PDR多重耐药菌暂行标准定义——国际专家建议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4fb154196dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991675, encodeId=1adb19916e570, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=J Antimicrob Chemother：治疗MDR和XDR-AB感染粘菌素+舒巴坦或是一个不错的选择！, objectType=article, longId=128271, objectId=ae071282e1df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae071282e1df, replyNumber=0, likeNumber=56, createdTime=2018-12-31, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae071282e1df, moduleTitle=J Antimicrob Chemother：治疗MDR和XDR-AB感染粘菌素+舒巴坦或是一个不错的选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae071282e1df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991678, encodeId=68e119916e852, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=Infect Cont Hosp Ep：应对ICU的MDRO防控：普遍接触预防有必要吗？, objectType=article, longId=140507, objectId=932714050e0b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=932714050e0b, replyNumber=0, likeNumber=38, createdTime=2019-05-19, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=932714050e0b, moduleTitle=Infect Cont Hosp Ep：应对ICU的MDRO防控：普遍接触预防有必要吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=932714050e0b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991679, encodeId=3fa819916e950, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=Infect Cont Hosp Ep:MDRO感染，有一就有二？, objectType=article, longId=145083, objectId=8fe714508393, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fe714508393, replyNumber=0, likeNumber=41, createdTime=2018-11-16, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fe714508393, moduleTitle=Infect Cont Hosp Ep:MDRO感染，有一就有二？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fe714508393)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991676, encodeId=5c9b19916e60a, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=Antimicrob Agents Ch：HIV儿童：洛匹那韦-利托那韦与MDR-TB常用药联用时相互作用如何？, objectType=article, longId=131246, objectId=42ed13124630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42ed13124630, replyNumber=0, likeNumber=37, createdTime=2018-04-11, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42ed13124630, moduleTitle=Antimicrob Agents Ch：HIV儿童：洛匹那韦-利托那韦与MDR-TB常用药联用时相互作用如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42ed13124630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991674, encodeId=833d19916e49e, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=TUV南德解析欧盟MDR新法规下的临床要求, objectType=article, longId=113177, objectId=07ab1131e760, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07ab1131e760, replyNumber=0, likeNumber=40, createdTime=2018-04-02, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07ab1131e760, moduleTitle=TUV南德解析欧盟MDR新法规下的临床要求, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07ab1131e760)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991677, encodeId=afcd19916e77a, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=Int J Tuberc Lung Dis：在HIV共感染的MDR-TB患者中，氨基糖苷类诱导的听力损失风险增加, objectType=article, longId=140553, objectId=bf84140553c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf84140553c7, replyNumber=0, likeNumber=42, createdTime=2018-12-31, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf84140553c7, moduleTitle=Int J Tuberc Lung Dis：在HIV共感染的MDR-TB患者中，氨基糖苷类诱导的听力损失风险增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf84140553c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991673, encodeId=0d8b19916e31a, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=MDRD肌酐清除率计算公式, objectType=article, longId=44663, objectId=0bc844663e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bc844663e1, replyNumber=0, likeNumber=51, createdTime=2015-06-24, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bc844663e1, moduleTitle=MDRD肌酐清除率计算公式, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bc844663e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991672, encodeId=27d519916e26b, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, objectTitle=CID：三联疗法可有效预防接触MDR-TB的儿童感染肺结核, objectType=article, longId=25136, objectId=6c3e25136ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c3e25136ce, replyNumber=0, likeNumber=31, createdTime=2014-02-03, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c3e25136ce, moduleTitle=CID：三联疗法可有效预防接触MDR-TB的儿童感染肺结核, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c3e25136ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

MDR

2020-05-29

syscxl (审核中...)

前往app查看评论内容

#MDR#

Neurology：24例LGMDR12成人患者两年随访的前瞻性自然史研究：定量MRI和临床结果评估

2022-10-12

syscxl (审核中...)

前往app查看评论内容

#MDR#

沙巍解读：在MDR-TB高负担国家推广贝达喹啉对患者治疗结局的影响

2022-08-10

syscxl (审核中...)

前往app查看评论内容

#MDR#

数坤冠脉AI、肺炎AI获欧盟MDR CE证书智能医疗健康服务普惠全球医患

2021-07-17

syscxl (审核中...)

前往app查看评论内容

#MDR#

Brit J Cancer：D133可通过AKT/NF-κB/MDR1通路逆转结直肠癌的耐药性

2020-06-29

syscxl (审核中...)

前往app查看评论内容

#MDR#

CIMDR苏州举办，TUV南德专业解读医疗器械领域新近法规

2019-11-12

syscxl (审核中...)

前往app查看评论内容

#MDR#

TUV南德正式获得欧盟医疗器械新法规 (MDR) 发证资质授权

2020-04-07

syscxl (审核中...)

前往app查看评论内容

#MDR#

MDR、XDR、PDR多重耐药菌暂行标准定义——国际专家建议

2019-05-05

syscxl (审核中...)

前往app查看评论内容

#MDR#

J Antimicrob Chemother：治疗MDR和XDR-AB感染粘菌素+舒巴坦或是一个不错的选择！

2018-12-31

syscxl (审核中...)

前往app查看评论内容

#MDR#

Infect Cont Hosp Ep：应对ICU的MDRO防控：普遍接触预防有必要吗？

2019-05-19

syscxl (审核中...)

前往app查看评论内容

#MDR#

Infect Cont Hosp Ep:MDRO感染，有一就有二？

2018-11-16

syscxl (审核中...)

前往app查看评论内容

#MDR#

Antimicrob Agents Ch：HIV儿童：洛匹那韦-利托那韦与MDR-TB常用药联用时相互作用如何？

2018-04-11

syscxl (审核中...)

前往app查看评论内容

#MDR#

TUV南德解析欧盟MDR新法规下的临床要求

2018-04-02

syscxl (审核中...)

前往app查看评论内容

#MDR#

Int J Tuberc Lung Dis：在HIV共感染的MDR-TB患者中，氨基糖苷类诱导的听力损失风险增加

2018-12-31

syscxl (审核中...)

前往app查看评论内容

#MDR#

MDRD肌酐清除率计算公式

2015-06-24

syscxl (审核中...)

前往app查看评论内容

#MDR#

CID：三联疗法可有效预防接触MDR-TB的儿童感染肺结核

2014-02-03

科室
- - 订阅+
  - 更多科室
工具
服务